ASCO: Bayer Vitrakvi Long-Term Efficacy and Safety Profile in NTRK Gene Fusion Cancer, Across Solid Tumors

• Post-hoc subgroup analyses of adult patients (n=180) with TRK fusion cancer across 24 different tumor types, including patients with central nervous system (CNS) metastases (n=22), were presented. All efficacy assessments were by IRC.¹
• Long-term follow-up of subgroup analyses of patients with advanced TRK fusion lung cancer (n=30), including those with CNS metastases (n=12), were also presented.²
• Additionally, separate subset analyses of three clinical trials evaluating patients with NTRK gene fusion thyroid cancer (n=30) were presented.³ 

https://www.biospace.com/article/releases/latest-vitrakvi-larotrectinib-subgroup-analyses-at-asco-2023-showcase-long-term-efficacy-and-safety-profile-in-adult-and-pediatric-patients-with-ntrk-gene-fusion-cancer-across-solid-tumors/